Abstract
ImportanceBlood pressure (BP) is a known risk factor for overall mortality and cardiovascular (CV)-specific fatal and nonfatal outcomes. It is uncertain which BP index is most strongly associated with these outcomes. ObjectiveTo evaluate the association of BP indexes with death and a composite CV event. Design, Setting, and ParticipantsLongitudinal population-based cohort study of 11135 adults from Europe, Asia, and South America with baseline observations collected from May 1988 to May 2010 (last follow-ups, August 2006-October 2016). ExposuresBlood pressure measured by an observer or an automated office machine; measured for 24 hours, during the day or the night; and the dipping ratio (nighttime divided by daytime readings). Main Outcomes and MeasuresMultivariable-adjusted hazard ratios (HRs) expressed the risk of death or a CV event associated with BP increments of 20/10 mm Hg. Cardiovascular events included CV mortality combined with nonfatal coronary events, heart failure, and stroke. Improvement in model performance was assessed by the change in the area under the curve (AUC). ResultsAmong 11135 participants (median age, 54.7 years, 49.3% women), 2836 participants died (18.5 per 1000 person-years) and 2049 (13.4 per 1000 person-years) experienced a CV event over a median of 13.8 years of follow-up. Both end points were significantly associated with all single systolic BP indexes (P
| Original language | English |
|---|---|
| Pages (from-to) | 409-420 |
| Number of pages | 12 |
| Journal | JAMA-Journal of the American Medical Association |
| Volume | 322 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 6 Aug 2019 |
Keywords
- CORONARY-HEART-DISEASE
- HYPERTENSION
- PATTERN
- PREDICTION
- PREVENTION
- RISK
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JAMA-Journal of the American Medical Association, Vol. 322, No. 5, 06.08.2019, p. 409-420.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes
AU - Yang, W. -Y.
AU - Melgarejo, Jesus D.
AU - Thijs, Lutgarde
AU - Zhang, Zhen-Yu
AU - Boggia, Jose
AU - Wei, F. -F.
AU - Hansen, Tine W.
AU - Asayama, Kei
AU - Ohkubo, T.
AU - Jeppesen, Jorgen
AU - Dolan, Eamon
AU - Stolarz-Skrzypek, K.
AU - Malyutina, Sofia
AU - Casiglia, E.
AU - Lind, Lars
AU - Filipovsky, Jan
AU - Maestre, G.
AU - Li, Yan
AU - Wang, Ji-Guang
AU - Imai, Yutaka
AU - Kawecka-Jaszcz, K.
AU - Sandoya, Edgardo
AU - Narkiewicz, Krzysztof
AU - O'Brien, Eoin
AU - Verhamme, Peter
AU - Staessen, Jan A.
AU - Mujaj, B.
AU - Cauwenberghs, N.
AU - Kuznetsova, T.
AU - Thijs, L.
AU - Yu, C. -G.
AU - Zhang, Z. -Y.
AU - Li, Y.
AU - Sheng, C. -S.
AU - Huang, Q. -F.
AU - Wang, J. -G.
AU - Filipovsky, J.
AU - Seidlerova, J.
AU - Ticha, M.
AU - Hansen, T. W.
AU - Ibsen, H.
AU - Jeppesen, J.
AU - Rasmussen, S.
AU - Torp-Pedersen, C.
AU - Dolan, E.
AU - O'Brien, E.
AU - Int Database Ambulatory Blood
N1 - Funding Information: Belgium: grants HEALTH-F7-305507 HOMAGE from the European Union; advanced researcher grant 2011-294713-EPLORE and proof-of-concept grant 713601-uPROPHET from the European Research Council, JTC2017-046-PROACT from the European Research Area Net for Cardiovascular Diseases; and G.0881.13 from the Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium; China: grants 81170245, 81270373, 81470533, and 91639203 from the National Natural Science Foundation of China; 2013CB530700 from the Ministry of Science and Technology; 1012 from the China-European Union Collaboration, Beijing, China; 14ZR1436200 and 15XD1503200 from the Shanghai Commission of Science and Technology; and 20152503 from the Gaofeng Clinical Medicine Education; Czech Republic: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union and P36 from Charles University research fund project; Denmark: 01-2-9-9A-22914 from the Danish Heart Foundation and R32-A2740 from the Lundbeck Fonden; Ireland: the Irish Allied Bank; Italy: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; Japan: 16H05243, 16H05263, 16K09472, 16K11850, 16K15359, 17H04126, 17H06533, 17K15853, 17K19930, 18K09674, 18K09904, and 18K17396 from the Ministry of Culture, Sports, Science and Technology; grant-in-aid H28-4 for young scientists of Showa Pharmaceutical University, Japan Atherosclerosis Prevention Fund (comprehensive research on cardiovascular and lifestyle related diseases); H26-Junkankitou (Seisaku)-Ippan-001 and H29-Junkankitou-Ippan-003 from the Ministry of Health, Labor, andWelfare; NouEi 2-02 from the Ministry of Agriculture, Forestry and Fisheries; Academic Contributions from Pfizer Japan Inc; and scholarship donations from Chugai Pharmaceutical Company and Daiichi Sankyo Co; Poland (Gda?sk): LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; Poland (Krak-w): LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union and Foundation for Polish Science; Russian Federation: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; Uruguay: Asociacion Espanola Primera en Salud; Venezuela: 1-R01AG036469 A1 from the US National Institute of Aging and the Fogarty International Center, 1-R03 AG054186-01 from the US National Institutes of Health and National Institute of Aging; FONACIT, G-97000726 from Caracas; and LOCTI/008-2008 from FundaConCiencia, Maracaibo. Funding Information: HEALTH-F7-305507 HOMAGE from the European Union; advanced researcher grant 2011-294713-EPLORE and proof-of-concept grant 713601-uPROPHET from the European Research Council, JTC2017-046-PROACT from the European Research Area Net for Cardiovascular Diseases; and G.0881.13 from the Research Foundation Flanders, Ministry of the Flemish Community, Brussels, Belgium; China: grants 81170245, 81270373, 81470533, and 91639203 from the National Natural Science Foundation of China; 2013CB530700 from the Ministry of Science and Technology; 1012 from the China-European Union Collaboration, Beijing, China; 14ZR1436200 and 15XD1503200 from the Shanghai Commission of Science and Technology; and 20152503 from the Gaofeng Clinical Medicine Education; Czech Republic: LSHM-CT-2006– 037093 and HEALTH-F4-2007-201550 from the European Union and P36 from Charles University research fund project; Denmark: 01-2-9-9A-22914 from the Danish Heart Foundation and R32-A2740 from the Lundbeck Fonden; Ireland: the Irish Allied Bank; Italy: LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; Japan: 16H05243, 16H05263, 16K09472, 16K11850, 16K15359, 17H04126, 17H06533, 17K15853, 17K19930, 18K09674, 18K09904, and 18K17396 from the Ministry of Culture, Sports, Science and Technology; grant-in-aid H28-4 for young scientists of Showa Pharmaceutical University, Japan Atherosclerosis Prevention Fund (comprehensive research on cardiovascular and lifestyle related diseases); H26-Junkankitou (Seisaku)-Ippan-001 and H29-Junkankitou-Ippan-003 from the Ministry of Health, Labor, and Welfare; NouEi 2-02 from the Ministry of Agriculture, Forestry and Fisheries; Academic Contributions from Pfizer Japan Inc; and scholarship donations from Chugai Pharmaceutical Company and Daiichi Sankyo Co; Poland (Gdańsk): LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union; Poland (Kraków): LSHM-CT-2006-037093 and HEALTH-F4-2007-201550 from the European Union and Foundation for Polish Science; Russian Federation: LSHM-CT-2006–037093 and HEALTH-F4-2007–201550 from the European Union; Uruguay: Asociación Española Primera en Salud; Venezuela: 1-R01AG036469 A1 from the US National Institute of Aging and the Fogarty International Center, 1-R03 AG054186-01 from the US National Institutes of Health and National Institute of Aging; FONACIT, G-97000726 from Caracas; and LOCTI/008-2008 from FundaConCiencia, Maracaibo. Publisher Copyright: © 2019 American Medical Association. All rights reserved.
PY - 2019/8/6
Y1 - 2019/8/6
N2 - ImportanceBlood pressure (BP) is a known risk factor for overall mortality and cardiovascular (CV)-specific fatal and nonfatal outcomes. It is uncertain which BP index is most strongly associated with these outcomes. ObjectiveTo evaluate the association of BP indexes with death and a composite CV event. Design, Setting, and ParticipantsLongitudinal population-based cohort study of 11135 adults from Europe, Asia, and South America with baseline observations collected from May 1988 to May 2010 (last follow-ups, August 2006-October 2016). ExposuresBlood pressure measured by an observer or an automated office machine; measured for 24 hours, during the day or the night; and the dipping ratio (nighttime divided by daytime readings). Main Outcomes and MeasuresMultivariable-adjusted hazard ratios (HRs) expressed the risk of death or a CV event associated with BP increments of 20/10 mm Hg. Cardiovascular events included CV mortality combined with nonfatal coronary events, heart failure, and stroke. Improvement in model performance was assessed by the change in the area under the curve (AUC). ResultsAmong 11135 participants (median age, 54.7 years, 49.3% women), 2836 participants died (18.5 per 1000 person-years) and 2049 (13.4 per 1000 person-years) experienced a CV event over a median of 13.8 years of follow-up. Both end points were significantly associated with all single systolic BP indexes (P
AB - ImportanceBlood pressure (BP) is a known risk factor for overall mortality and cardiovascular (CV)-specific fatal and nonfatal outcomes. It is uncertain which BP index is most strongly associated with these outcomes. ObjectiveTo evaluate the association of BP indexes with death and a composite CV event. Design, Setting, and ParticipantsLongitudinal population-based cohort study of 11135 adults from Europe, Asia, and South America with baseline observations collected from May 1988 to May 2010 (last follow-ups, August 2006-October 2016). ExposuresBlood pressure measured by an observer or an automated office machine; measured for 24 hours, during the day or the night; and the dipping ratio (nighttime divided by daytime readings). Main Outcomes and MeasuresMultivariable-adjusted hazard ratios (HRs) expressed the risk of death or a CV event associated with BP increments of 20/10 mm Hg. Cardiovascular events included CV mortality combined with nonfatal coronary events, heart failure, and stroke. Improvement in model performance was assessed by the change in the area under the curve (AUC). ResultsAmong 11135 participants (median age, 54.7 years, 49.3% women), 2836 participants died (18.5 per 1000 person-years) and 2049 (13.4 per 1000 person-years) experienced a CV event over a median of 13.8 years of follow-up. Both end points were significantly associated with all single systolic BP indexes (P
KW - CORONARY-HEART-DISEASE
KW - HYPERTENSION
KW - PATTERN
KW - PREDICTION
KW - PREVENTION
KW - RISK
U2 - 10.1001/jama.2019.9811
DO - 10.1001/jama.2019.9811
M3 - Article
SN - 0098-7484
VL - 322
SP - 409
EP - 420
JO - JAMA-Journal of the American Medical Association
JF - JAMA-Journal of the American Medical Association
IS - 5
ER -